Horizon Pharma plc

Horizon Pharma plc

Horizon Pharma plc was founded in 2005 as a specialty pharmaceutical company focused on developing and commercializing medicines for rare, autoimmune, and inflammatory diseases. The firm went public on NASDAQ in 2011 under the ticker HZNP, led by co-founder and CEO Timothy Walbert, who built a portfolio centered around orphan drug designations. Wealth for the entity came from public equity markets, not a single family fortune. Horizon's investment strategy involved acquiring and scaling approved drugs with strong clinical data but underappreciated commercial potential. Key assets included Krystexxa for chronic gout, Tepezza for thyroid eye disease, and Ravicti for urea cycle disorders. The company's geographic footprint spanned the United States, Europe, and Japan, with subsidiaries in Illinois, Germany, and the UK. At the time of Amgen's acquisition, Horizon employed roughly 2,300 people and generated annual revenue exceeding $3.6 billion (per SEC filings, 2022). The October 2021 acquisition was completed in October 2022 after overcoming FTC opposition, marking a major operational event in the firm's timeline. No philanthropic foundations or separate investment vehicles are publicly associated with Horizon. Horizon's structural differentiator was its rare-disease commercial model — it built a specialty sales force targeting a small number of high-cost drugs rather than a broad R&D pipeline. That model made it an attractive acquisition target for Amgen, which sought to expand its own rare-disease portfolio. The firm's transition from public entity to Amgen subsidiary represents its defining governance shift.